The changing therapeutic landscape of castration-resistant prostate cancer
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The changing therapeutic landscape of castration-resistant prostate cancer
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 8, Issue 10, Pages 597-610
Publisher
Springer Nature
Online
2011-08-09
DOI
10.1038/nrclinonc.2011.117
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Current and emerging treatment modalities for metastatic castration-resistant prostate cancer
- (2011) Sergio Bracarda et al. BJU INTERNATIONAL
- Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
- (2011) Timothy A. Yap et al. CA-A CANCER JOURNAL FOR CLINICIANS
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
- (2011) David J. Mulholland et al. CANCER CELL
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Small Molecule Inhibitors Targeting the “Achilles' Heel” of Androgen Receptor Activity: Figure 1.
- (2011) Marianne D. Sadar CANCER RESEARCH
- Eight-Signature Classifier for Prediction of Nasopharyngeal Carcinoma Survival
- (2011) Hai-Yun Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
- (2011) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Reply to P.A. Meyers et al
- (2011) Brigitte C. Widemann et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of a New Risk Assessment Model for Predicting Adverse Events in Children With Fever and Chemotherapy-Induced Neutropenia
- (2011) Karin G.E. Miedema et al. JOURNAL OF CLINICAL ONCOLOGY
- Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
- (2011) Richard D. Kennedy et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF targeted therapy changes the treatment paradigm in melanoma
- (2011) Antoni Ribas et al. Nature Reviews Clinical Oncology
- A decade in prostate cancer: from NMR to metabolomics
- (2011) Elita M. DeFeo et al. Nature Reviews Urology
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer
- (2011) Evan Y. Yu et al. UROLOGY
- A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer
- (2010) Srikala S. Sridhar et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth
- (2010) Manolis A. Fousteris et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
- (2010) Jean-Christophe Eymard et al. BJU INTERNATIONAL
- Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,
- (2010) Nicholas D. James et al. BJU INTERNATIONAL
- The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
- (2010) L R Molife et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer
- (2010) Joel Picus et al. CANCER
- Aberrant Activation of the Androgen Receptor by NF- B2/p52 in Prostate Cancer Cells
- (2010) N. Nadiminty et al. CANCER RESEARCH
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
- (2010) M.-L. Zhu et al. CANCER RESEARCH
- Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
- (2010) J. Baselga et al. CLINICAL CANCER RESEARCH
- Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
- (2010) M. Yamaoka et al. CLINICAL CANCER RESEARCH
- Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
- (2010) T. B. Dorff et al. CLINICAL CANCER RESEARCH
- Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer
- (2010) B. Wegiel et al. CURRENT CANCER DRUG TARGETS
- RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?
- (2010) H. C. Whitaker et al. CURRENT CANCER DRUG TARGETS
- Utilizing circulating tumor cells: challenges and pitfalls
- (2010) Gerhardt Attard et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- RETRACTED: Horizon scanning for novel therapeutics for the treatment of prostate cancer
- (2010) Diletta Bianchini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor
- (2010) X. Edward Zhou et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Castration-Dependent Pharmacokinetics of Docetaxel in Patients With Prostate Cancer
- (2010) Ryan M. Franke et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Yang-Min Ning et al. JOURNAL OF CLINICAL ONCOLOGY
- Longitudinal Study of Depressive Symptoms in Patients With Metastatic Gastrointestinal and Lung Cancer
- (2010) Christopher Lo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T
- (2010) Celestia S. Higano et al. NATURE REVIEWS DRUG DISCOVERY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
- (2009) G. Sonpavde et al. ANNALS OF ONCOLOGY
- Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
- (2009) C. N. Sternberg et al. ANNALS OF ONCOLOGY
- Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
- (2009) L. R. Molife et al. ANNALS OF ONCOLOGY
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer
- (2009) József Horti et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
- (2009) L. Fong et al. CANCER RESEARCH
- Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
- (2009) G. Attard et al. CANCER RESEARCH
- An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
- (2009) G. Liu et al. CLINICAL CANCER RESEARCH
- Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors
- (2009) W. P. Tew et al. CLINICAL CANCER RESEARCH
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors
- (2009) A. C. Mita et al. CLINICAL CANCER RESEARCH
- Anti—Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab Plus Doxorubicin in the Treatment of Metastatic Castration-Resistant Prostate Cancer
- (2009) Susan F. Slovin et al. Clinical Genitourinary Cancer
- Effects of Tamoxifen and Raloxifene on Memory and Other Cognitive Abilities: Cognition in the Study of Tamoxifen and Raloxifene
- (2009) Claudine Legault et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
- (2009) Yu Chen et al. LANCET ONCOLOGY
- Ligand-independent activation of the androgen receptor by insulin-like growth factor-i and the role of the MAPK pathway in skeletal muscle cells
- (2009) Hye Jin Kim et al. MOLECULES AND CELLS
- PSA as an intermediate end point in clinical trials
- (2009) Gerhardt Attard et al. Nature Reviews Urology
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion
- (2009) William P Harris et al. Nature clinical practice. Urology
- A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
- (2008) X. Pivot et al. ANNALS OF ONCOLOGY
- A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones
- (2008) Mary-Ellen Taplin et al. BJU INTERNATIONAL
- The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens
- (2008) Liang Schweizer et al. BMC CELL BIOLOGY
- Fusion in the ETS gene family and prostate cancer
- (2008) S A Narod et al. BRITISH JOURNAL OF CANCER
- Antiandrogen withdrawal in castrate-refractory prostate cancer
- (2008) A. Oliver Sartor et al. CANCER
- Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer
- (2008) Joel B. Nelson et al. CANCER
- A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
- (2008) W. L. Dahut et al. CLINICAL CANCER RESEARCH
- A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer
- (2008) A. J. Armstrong et al. CLINICAL CANCER RESEARCH
- A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
- (2008) E. I. Heath et al. CLINICAL CANCER RESEARCH
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
- (2008) J. S. de Bono et al. CLINICAL CANCER RESEARCH
- Targeting CYP17: established and novel approaches in prostate cancer
- (2008) Timothy A Yap et al. CURRENT OPINION IN PHARMACOLOGY
- Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
- (2008) Nicholas D. James et al. EUROPEAN UROLOGY
- ERRATUM
- (2008) JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
- (2008) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Prednisone plus Gefitinib versus Prednisone plus Placebo in the Treatment of Hormone-Refractory Prostate Cancer: A Randomized Phase II Trial
- (2008) Francesco Boccardo et al. ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search